VolitionRx Limited, a multi-national epigenetics company, has entered a collaboration with Sysmex, a leader in global in vitro diagnostics, to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex platform. The partnership focuses on enhancing the assay's performance and compatibility with Sysmex's diagnostic systems.

Collaboration Details

The collaboration leverages Sysmex's expertise in in vitro diagnostics to refine the Nu.Q NETs H3.1 assay. This assay is designed to detect nucleosomes, which are biomarkers associated with various diseases, including cancer. By optimizing the assay for the Sysmex platform, Volition aims to improve its accessibility and utility in clinical settings.

Strategic Implications

This partnership aligns with VolitionRx's strategy to expand the reach of its epigenetic diagnostics solutions. Sysmex's established global presence and diagnostic infrastructure provide a robust foundation for the deployment of the optimized assay. The collaboration is expected to enhance the assay's adoption in laboratories worldwide.

Key Objectives

• Optimize the Nu.Q NETs H3.1 assay for the Sysmex platform.
• Improve assay performance and integration with Sysmex's diagnostic systems.
• Expand the clinical utility and accessibility of the assay.

The collaboration underscores the growing importance of epigenetic diagnostics in precision medicine and early disease detection.